Sterile Hyaluronic Acid: Powering HA-based Next Generation of Medical Innovation

Sterile HA production unit

HTL Biotechnology has inaugurated this year a new sterile HA production unit. Importantly, HTL Biotechnology is today the only producer in Europe capable of delivering sterile hyaluronic acid, reinforcing our position as a strategic partner for healthcare innovators. By offering this unique material, HTL Biotechnology empowers its partners to innovate faster and safer, shaping the future of biopolymer-based medicine.

Hyaluronic Acid: A Cornerstone of Modern Medicine

Hyaluronic acid (HA), or sodium hyaluronate, has established itself as a cornerstone molecule across multiple medical fields. Its unique properties such as biocompatibility, hydrophilicity and biodegradability make it indispensable in ophthalmology, rheumatology, and medical aesthetic. Furthermore, its potential is widely studied today in drug delivery.

For decades, HTL Biotechnology has supplied pharmaceutical-grade HA of exceptional purity, with very low protein and endotoxin levels, produced under strict GMP standards. This HA is the benchmark raw material for countless pharmaceutical and medical device formulations worldwide.

Powering Next-Gen Drug Delivery system with Sterile HA

HTL’s pharmaceutical-grade HA is the industry standard for all of medical applications and continues to be a biomaterial that drives medical innovation.

Sterile HA is a complementary solution for highly specific, innovative projects that require aseptic HA. Its main advantage is that it enables combination with thermosensitive actives or biomolecules that would be degraded by heat-based sterilization. It removes the need for additional sterilization steps and paves the way for advanced drug delivery systems.

With over 30 years of expertise and excellence in pharmaceutical-grade HA, and now sterile HA, HTL Biotechnology is the trusted partner for supporting healthcare innovation.